John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 13,259 shares at $183.19 ($2.4M) on 2021-04-01, disclosed to the SEC on 2021-04-02.
Open-market sale of $2.4M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $180.27 | 241 | $43K | 1.8% |
| 2 | $181.83 | 200 | $36K | 1.5% |
| 3 | $183.19 | 700 | $128K | 5.2% |
| 4 | $184.22 | 2,272 | $419K | 17.1% |
| 5 | $184.22 | 2,272 | $419K | 17.1% |
| 6 | $185.21 | 3,487 |
| $646K |
| 26.4% |
| 7 | $185.21 | 3,487 | $646K | 26.4% |
| 8 | $185.90 | 600 | $112K | 4.6% |
| Total | $184.65 avg | 13,259 | $2.4M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |